A synthetic protein can treat severe insulin resistance by using a completely different key to unlock the body's sugar-processing cells.
Severe insulin resistance happens when the receptors on cells become so damaged that they no longer respond to the insulin hormone. Scientists created a de novo protein called RF-409 that activates these receptors from a completely different angle. In tests on mice, this synthetic protein successfully lowered blood sugar even when traditional insulin injections failed completely. It works by bypassing the broken part of the receptor and triggering the necessary biological response through a new pathway. This discovery could lead to a cure for late-stage type 2 diabetes and other metabolic diseases that currently have no effective treatment.
Reprogramming insulin receptor activation with a de novo agonist to overcome severe insulin resistance
bioRxiv · 10.64898/2026.05.04.722722
Computational protein engineering provides a powerful approach to address longstanding clinical challenges. Severe insulin resistance syndromes caused by mutations in the insulin receptor (IR) are life-threatening disorders for which effective long-term therapies remain lacking. Here, we define the in vivo activity and therapeutic potential of RF-409, a de novo-designed IR agonist that activates the receptor through a mechanism distinct from insulin. RF-409 exhibits markedly prolonged circulatio